TACE Plus Axitinib and Hydroxychlorquine for Liver-Dominant Metastatic Colorectal Cancer (CRC)

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

April 25, 2024

Study Completion Date

April 25, 2024

Conditions

Colorectal Neoplasms Malignant

Interventions

DRUG

Axitinib 5 MG

axitinib 5 mg po BID until progression or intolerance

DRUG

Hydroxychloroquine Pill

hydroxychloroquine 600 mg po BID until progression or intolerance

PROCEDURE

trans arterial chemoembolization

segmental or lobar TACE at 4-8 week intervals until entire tummy burden is treated.

Trial Locations (1)

Abramson Cancer Center, Philadelphia